Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market ccess
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices
Meeting the Standards of Normal Science in Health Outcomes and Market Access for Pharmaceutical Products and Devices

Maimon Working Papers

 Maimon Working Papers in formulary evaluations and health technology assessment present versions of papers that have been submitted to journals. These are typically extended versions of final publications, where for purposes of space and presentation they may have been modified for publication. The Maimon Working Papers are free to download (in PDF format).

Why ICER has failed
Working Paper No. 26 November 2020.pdf
Adobe Acrobat document [990.3 KB]
To Dream the Impossible Dream: The commitment by the Institute for Clinical and Economic Review to rewrite the axioms of fundamental measurement for Hemophilia A and Bladder Cancer value claims
Working Paper No. 25 November 2020.pdf
Adobe Acrobat document [1.2 MB]
More ICER nonsense on severe hemophilia A: The University of Illinois modelled evidence report for valoctocogene roxapavovec and emicizumab
Working Paper No. 24 October 2020.pdf
Adobe Acrobat document [983.6 KB]
Value Assessment, Real World Evidence and Fundamental Measurement: Version 3.0 of the Minnesota Formulary Submission Guidelines
Working paper No. 23 October 2020.pdf
Adobe Acrobat document [1.1 MB]
More Covid-19 Nonsense: The ICER modelled threshold price benchmarks for Remdesivir
Working Paper No. 22 October 2020.pdf
Adobe Acrobat document [708.6 KB]
Formulary Design, Fair Price and Fair Access for Pharmaceuticals:
The Institute for Clinical and Economic Review and Office of Health Economics White Paper Falls at the First Hurdle
Working Paper No. 21 October 2020.pdf
Adobe Acrobat document [816.6 KB]
Meaningless Magical Measures: ICER's Bizarre Belief in the EQ-5D Ratio Scale
Working Paper No. 20 September 2020.pdf
Adobe Acrobat document [904.0 KB]
Measurement Malpractice: Composite patient reported outcomes
Working Paper No. 19 August 2020.pdf
Adobe Acrobat document [707.4 KB]
The Great I-QALY Disaster (Version 2)
Working Paper No. 18 August 2020.pdf
Adobe Acrobat document [754.2 KB]
Impossible QALYs and the ICER Evidence Report for NASH: Avoiding Nonsensical Recommendations
Working Paper No. 17 July 2020.pdf
Adobe Acrobat document [623.9 KB]
Damaged Goods: Imaginary ICER value assessments and the Veterans Administration
Working Paper No. 16 July 2020.pdf
Adobe Acrobat document [631.1 KB]
The great I-QALY disaster
Working Paper No. 15 June 2020.pdf
Adobe Acrobat document [805.4 KB]
Introducing the I-QALY: The Imaginary Construct Supporting Health Technology Assessment
Working Paper No. 14 June 2020.pdf
Adobe Acrobat document [999.3 KB]
More Unnecessary Imaginary Worlds: The University of Washington Modelled Value Assessment of Targeted Immune Modulators In Ulcerative Colitis for the Institute for Clinical and Economic Review
Working Paper No. 13 May 2020.pdf
Adobe Acrobat document [1'021.2 KB]
The National Pharmaceutical Council: Endorsing the Construction of Imaginary Worlds In Health Technology Assessment
Working Paper No. 12 May 2020.pdf
Adobe Acrobat document [977.9 KB]
Manifest Nonsense: Cosmin and the Axioms of Fundamental Measurement in the Checklist for Systematic Reviews
Working Paper No. 11 May 2020.pdf
Adobe Acrobat document [837.5 KB]
Evidence Framework for Rare and Chronic Diseases
Working Paper No. 10 May 2020.pdf
Adobe Acrobat document [783.0 KB]
To Dream the Impossible Dream: The EQ-5D QALY
Working Paper No. 9 April 2020 V2.pdf
Adobe Acrobat document [868.7 KB]
Post Nubes Lux: Beyond Reference Case Imaginary Worlds to Real World Evidence in Health Technology Assessment.
Working Paper No. 8 March 2020.pdf
Adobe Acrobat document [338.8 KB]
Where Ignorance is Bliss: The ICER Draft Evidence Report Modeling Imaginary Worlds for Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis (NASH) with Fibrosis
Working Paper No. 7 March 2020.pdf
Adobe Acrobat document [288.8 KB]
Working Paper No. 6 March 2020 More Unnecessary Imaginary Worlds: The ICER Final Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease
Working Paper No. 6 March 2020.pdf
Adobe Acrobat document [276.8 KB]
Working Paper No. 5 March 2020 Evading the Question: The EQ-5D and ICER’s Rejection of Fundamental Measurement in Fabricating Imaginary Worlds
Working Paper No. 5 March 2020.pdf
Adobe Acrobat document [396.3 KB]
Working Paper No. 4/2020 Anticipating Imaginary Claims: The ICER Modeling Analysis Plan for Targeted Immune Modulators in Ulcerative Colitis
Working Paper No 4 March 2020.pdf
Adobe Acrobat document [237.9 KB]
Working Paper No. 3/2020 Deconstructing the Imaginary Worlds of ICER
Working Paper No. 3 2020.pdf
Adobe Acrobat document [337.4 KB]
Working Paper No.2/2020 More Unnecessary Imaginary Worlds: The Institute for Clinical and Economic Review’s Final Evidence Report and Recommendations for Acute Migraine Therapies
Working Paper No. 2 2020.pdf
Adobe Acrobat document [319.4 KB]
Working Paper No 1/2020: More Unnecessary Imaginary Worlds: Cystic Fibrosis and the Institute for Clinical and Economic Review’s Draft Evidence Report
No. 1 Cystic Fibrosis REV.pdf
Adobe Acrobat document [313.5 KB]
Print Print | Sitemap
© Maimon Research LLC